Enteromix, an mRNA-based cancer vaccine, is making headlines for demonstrating "100% efficiency" and showing no serious side effects in early clinical trials, raising hopes for a revolutionary breakthrough in oncology. Developed in Russia, the vaccine trains the immune system to recognise and destroy cancer cells while shrinking tumours.